Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term SURVIVAL. Found 43 abstracts

no pagination
Chen DY, Uzzo RG, Viterbo R. Thinking beyond surgery in the management of renal cell carcinoma: the risk to die from renal cell carcinoma and competing risks of death. [Review]. World journal of urology. 2014 Jun;32(3):607-13.   PMCID: No NIH funding
Corless CL, Ballman KV, Antonescu CR, Kolesnikova V, Maki RG, Pisters PW, Blackstein ME, Blanke CD, Demetri GD, Heinrich MC, von Mehren M, Patel S, McCarter MD, Owzar K, DeMatteo RP. Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial. Journal of Clinical Oncology. 2014 May;32(15):1563-70.   PMCID: PMC 4026579
Denlinger CS, Meropol NJ, Li T, Lewis NL, Engstrom PF, Weiner LM, Cheng JD, Alpaugh RK, Cooper H, Wright JJ, Cohen SJ. A Phase II Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Biliary Tract Cancers. Clinical Colorectal Cancer. 2014 Jun;13(2):81-6.   PMCID: Pmc4189831
Gao WZ, Ma GX, Tan Y, Fang C, Weaver J, Jin M, Lai P, Godwin AK. Culturally Appropriate Education Intervention on Biospecimen Research Participation among Chinese Americans. Cancer Epidemiology Biomarkers & Prevention. 2014 Mar;23(3):383-91.   PMCID: PMC 3955025
Gustafson HL, Yao S, Goldman BH, Lee K, Spier CM, LeBlanc ML, Rimsza LM, Cerhan JR, Habermann TM, Link BK, Maurer MJ, Slager SL, Persky DO, Miller TP, Fisher RI, Ambrosone CB, Briehl MM. Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma. American journal of hematology. 2014 Jun;89(6):639-45.   PMCID: 4137041
Pei JM, Robu V, Feder M, Cheung M, Neumann-Domer E, Talarchek J, Dulaimi E, Millenson MM, Testa JR. Copy neutral loss of heterozygosity in 20q in chronic lymphocytic leukemia/small lymphocytic lymphoma. Cancer Genetics. 2014 Mar;207(3):98-102.
Adams SF, Levine DA, Cadungog MG, Hammond R, Facciabene A, Olvera N, Rubin SC, Boyd J, Gimotty PA, Coukos G. Intraepithelial T Cells and Tumor Proliferation. Cancer. 2009 Jul;115(13):2891-902.   PMCID: PMC2754811
Crispen PL, Viterbo R, Boorjian SA, Greenberg RE, Chen DY, Uzzo RG. Natural History, Growth Kinetics, and Outcomes of Untreated Clinically Localized Renal Tumors Under Active Surveillance. Cancer. 2009 Jul;115(13):2844-52.   PMCID: PMC2860784
DeMatteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K, ACOSOG Intergrp Adjuvant GIST Stud. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2009 Mar;373(9669):1097-104.   PMCID: PMC2915459
Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M. Phase II Trial of Neoadjuvant/Adjuvant Imatinib Mesylate (IM) for Advanced Primary and Metastatic/Recurrent Operable Gastrointestinal Stromal Tumor (GIST): Early Results of RTOG 0132/ACRIN 6665. Journal of surgical oncology. 2009 Jan;99(1):42-7.   PMCID: PMC2606912
Mehta MP, Shapiro WR, Phan SC, Gervais R, Carrie C, Chabot P, Patchell RA, Glantz MJ, Recht L, Langer C, Sur RK, Roa WH, Mahe MA, Fortin A, Nieder C, Meyers CA, Smith JA, Miller RA, Renschler MF. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs timeto neurologic progression in non-small-cell lung cancer patients with brain metases: results of a phase III trial. International Journal of Radiation Oncology Biology Physics. 2009 Mar;73(4):1069-76.   PMCID: not NIH funded
Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, Gaspar LE, Schefter TE. Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Liver Metastases. Journal of Clinical Oncology. 2009 Apr;27(10):1572-8.   PMCID: not NIH funded
Xu M, Sharma A, Hossain MZ, Wiest DL, Sen JM. Sustained Expression of Pre-TCR Induced beta-Catenin in Post-beta-Selection Thymocytes Blocks T Cell Development. Journal of Immunology. 2009 Jan;182(2):759-65.   PMCID: PMC 2701226
Bilimoria KY, Palis B, Stewart AK, Bentrem DJ, Freel AC, Sigurdson ER, Talamonti MS, Ko CY. Impact of tumor location on nodal evaluation for colon cancer. Diseases of the Colon & Rectum. 2008 Feb;51(2):154-61.
Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. Journal of Clinical Oncology. 2008 Feb;26(4):626-32.
Darcy KM, Brady WE, McBroom JW, Bell JG, Young RC, McGuire WP, Linnolia RI, Hendricks D, Bonome T, Farley JH. Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers: A Gynecologic Oncology Group study. Gynecologic Oncology. 2008 Dec;111(3):487-95.
Donate F, Parry GC, Shaked Y, Hensley H, Guan X, Beck I, Tel-Tsur Z, Plunkett ML, Manuia M, Shaw DE, Kerbel RS, Mazar AP. Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): Observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth. Clinical Cancer Research. 2008 Apr;14(7):2137-44.
Janne PA, Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P, Monberg M, Obasaju C, Kindler H. Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma. Journal of Clinical Oncology. 2008 Mar;26(9):1465-71.
Marks DI, Perez WS, He W, Zhang MJ, Bishop MR, Bolwell BJ, Bredeson CN, Copelan EA, Gale RP, Gupta V, Hale GA, Isola LM, Jakubowski AA, Keating A, Klumpp TR, Lazarus HM, Liesveld JL, Maziarz RT, McCarthy PL, Sabloff M, Schiller G, Sierra J, Tallman MS, Waller EK, Wiernik PH, Weisdorf DJ. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood. 2008 Jul;112(2):426-34.
Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Kudrimoti MR, Fromm ML, Haddock MG, Schaefer P, Willett CG, Rich TA. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma - A randomized controlled trial. JAMA-Journal of the American Medical Association. 2008 Mar;299(9):1019-26.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term SURVIVAL

SURVIVAL PROGNOSTIC-FACTORS Oncology CARCINOMA PHASE-III MUTATIONS RESECTION CANCER THERAPY PROGRESSION TUMORS BREAST-CANCER SURGERY TYROSINE KINASE INHIBITOR RECEPTOR MASSES EXPRESSION SOLID TUMORS Chronic lymphocytic leukemia EPITHELIAL OVARIAN-CANCER COMBINATION Non-small-cell lung cancer KIDNEY CANCER Whole brain radiotherapy IMATINIB MESYLATE RISING RATES PHASE-II LEIOMYOSARCOMAS RESISTANCE Urology & Nephrology PLATINUM-BASED CHEMOTHERAPY RECURRENT GENOMIC ALTERATIONS PREVENTION TEXAPHYRIN METAPHASE FAILURE GENE-MUTATIONS INCIDENCE DIAGNOSED MULTIPLE-MYELOMA IN-VIVO SDHA IMPACT DIFFERENTIATION imprinting MALIGNANCIES COLITIS PROGRAM RECURRENCE PRIMARY CYTOREDUCTIVE SURGERY TRIAL IMATINIB CHEMOTHERAPY LUNG EPIDEMIC National Cancer Data Base CISPLATIN SINGLE-AGENT POOR-PROGNOSIS VIABILITY GEMCITABINE IHC KIT LYMPH-NODES ROR-GAMMA-T SURGICAL-MANAGEMENT CHAIN END-POINTS COOPERATIVE-ONCOLOGY-GROUP Ovarian cancer neoadjuvant imatinib Overexpression C-KIT lymph HUMAN CHOLANGIOCARCINOMA CELLS surgery ENDOTHELIAL-CELLS INTEGRIN ALPHA(5)BETA(1) MANAGEMENT ENDOSTATIN RANDOMIZED-TRIAL ARRAY CURATIVE RESECTION CELL LUNG-CANCER TUMOR CISPLATIN-BASED CHEMOTHERAPY PROGNOSTIC-SIGNIFICANCE Prognostic measurement CO-MORBIDITY Bortezomib chromosome microarray analysis HOSPITAL VOLUME GYNECOLOGIC-ONCOLOGY-GROUP CHOP Genetics & Heredity OVER-EXPRESSION Motexafin gadolinium KAPPA-B DOSE CHEMOTHERAPY ST1571 Environmental & Occupational Health Public Renal cell carcinoma ACTIVE SURVEILLANCE BRAF MUTATIONS PACLITAXEL MYELODYSPLASTIC SYNDROMES EUROPEAN-ORGANIZATION PROGNOSIS Medical decision making RECOMMENDATIONS Prognostic markers Proteosome STAGE nodes MODEL CHARLSON COMORBIDITY INDEX COMMUNITY metastatic GIST CELL CARCINOMA SARCOMA-GROUP SBRT FOLLOW-UP p53 T cells ovarian cancer-surgical cytoreduction-tumor proliferation EFFICACY colon neoplasms INFILTRATING LYMPHOCYTES PLUS DEXAMETHASONE LEUKEMIA GROUP-B colectomy TRANSGENIC MICE Nomogram RADIATION-THERAPY Hematology growth kinetics active surveillance-kidney neoplasms EXPERIENCE INTRAHEPATIC CHOLANGIOCARCINOMA MORTALITY RESIDUAL DISEASE SIGNALS C-MYC MINIMUM NUMBER GIST DISOMY COLORECTAL-CANCER STEM-CELL TRANSPLANTATION RISING INCIDENCE NAD(P)H OXIDASE HISTOLOGIC TYPES
Last updated on Friday, December 06, 2019